← Eichor
Condition: Still Disease Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Still Disease

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Natural History, Genetics, and Pathophysiology of Systemic Juvenile Idiopathic Arthritis, Adult-Onset Still's Disease, a
Phase N/A · 1 location(s) · National Institute of Arthritis and Musculoskeletal and Skin · NCT03510442A Study on the Use of Canakinumab Among Familial Mediterranean Fever and Still's Disease Patients
Phase N/A · 1 location(s) · Novartis Pharmaceuticals · NCT07517250Thyroidectomy for Graves' Disease or Amiodarone-induced Thyrotoxicosis
Phase N/A · 15 location(s) · Andrea Goldmann · NCT06963203Hemophagocytic Lymphohistiocytosis (HLH) Evaluation and Research of Clinical, ImmUnoLogic and TranscriptomE Study
Phase N/A · 2 location(s) · National Institute of Allergy and Infectious Diseases (NIAID · NCT06339177AutoInflammatory Disease Alliance Registry (AIDA)
Phase N/A · 112 location(s) · University of Siena · NCT05200715Rheumatology Patient Registry and Biorepository
Phase N/A · 1 location(s) · Yale University · NCT04402086Pre-trial of Clinical Trial of Traditional Chinese Medicine Treatment for Elderly Patients With Coronary Heart Disease W
Phase 4 · 1 location(s) · China National Center for Cardiovascular Diseases · NCT07041359Ilaris NIS in Korea
Phase N/A · 1 location(s) · Novartis Pharmaceuticals · NCT06838143Obstructive Sleep Apnea Therapeutic Intervention for REsiDual Sleepiness
NA · 1 location(s) · NYU Langone Health · NCT06698809Acostill ( RaDiCo Cohort) (RaDiCo Acostill)
Phase N/A · 1 location(s) · Institut National de la Santé Et de la Recherche Médicale, F · NCT05927454A Study of Firsekibart Versus Anakinra in Adult-Onset Still's Disease
Phase N/A · 1 location(s) · Ruijin Hospital · NCT07191444Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Even
Phase 3 · 47 location(s) · AbbVie · NCT05609630A US Study That Observes How Parkinson's Disease Changes Over Time in Patients Who Still Have Movement Symptoms Despite
Phase N/A · 26 location(s) · Bayer · NCT07330258A Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Systemic Juvenile Idiopathic Arthritis (SKYP
Phase 2 · 32 location(s) · Sanofi · NCT02991469EACVI Study on Multimodality Cardiovascular Imaging of Inflammatory Cardiovascular Diseases
Phase N/A · 1 location(s) · Assistance Publique - Hôpitaux de Paris · NCT07077304Asymptomatic Bacteriuria in Pregnancy in Low- and Middle-IncomE Countries
Phase 3 · 7 location(s) · NICHD Global Network for Women's and Children's Health · NCT06723392To Evaluate the Efficacy and Safety of Genalumab for Injection in the Treatment of Active Systemic Juvenile Idiopathic A
NA · 10 location(s) · Changchun GeneScience Pharmaceutical Co., Ltd. · NCT05925452Comparison of NOM for ACLD Between Medical and Surgical Ward
Phase N/A · 1 location(s) · Ospedali Riuniti Trieste · NCT06265649Glycosylated Ferritin in Macrophagic Activation Syndromes
Phase N/A · 1 location(s) · Brugmann University Hospital · NCT02143986Placental Imaging Techniques
NA · 1 location(s) · Carilion Clinic · NCT06861309Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT
Phase 2 · 1 location(s) · Paul Szabolcs · NCT01962415A Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participant
Phase 2 · 22 location(s) · Novartis Pharmaceuticals · NCT07203001
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.